Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies

Evry, January 23, 2025- Genethon, a pioneer and leader in the research and development of gene therapies for rare diseases, and Eukarÿs, a biotechnology company developing a disruptive technology that significantly increases biomanufacturing yields, today announced the signing of a strategic partnership. The collaboration aims to reduce the production costs of gene therapy medicines by harnessing Eukarÿs’ proprietary C3P3 technology, an innovative messenger RNA (mRNA) expression system in mammalian cells.

Gene therapies offer immense hope for patients suffering from rare and common diseases. However, the biomanufacturing of these therapies remains complex and costly, representing a major obstacle to their development and commercialization. Improving production technologies and dramatically increasing biomanufacturing yields are therefore strategic goals to improve patient access to these cutting-edge therapies.

Eukarÿs has developed an engineered enzyme, C3P3, which significantly increases the production capacity of cells used for biopharmaceutical synthesis, by enhancing their mRNA synthesis capabilities. Combined with Genethon’s expertise and technologies, this innovative approach could significantly improve the production of AAV (Adeno-Associated Virus) vectors, one of the main vector types used to deliver therapeutic genes to patients.

As part of this collaboration, Genethon will contribute its expertise in AAV vector design and production, as well as its technologies and biomanufacturing facilities, while Eukarÿs will provide its patented C3P3 technology and deep expertise in mRNA synthesis.

Patrick Santambien, Director of Technological Development at Genethon – “For more than fifteen years, Genethon has been pushing the boundaries of gene therapy biomanufacturing by focusing on innovative approaches. Eukarÿs’ technology is truly disruptive to biomanufacturing in general and holds great promise for delivering gene therapy products based on AAV vectors under optimal conditions, while drastically reducing biomanufacturing costs. We are excited about this partnership, which could pave the way for much more affordable therapies.”

Guillaume Prunier, CEO of Eukarÿs – “We are very pleased and proud to partner with Genethon. Our enzyme, which is now commercially available, is universal and requires no adaptation, with two exceptions: lentiviruses and AAV. Given the importance of gene therapy for patients with serious diseases and the industrial challenge it represents, we are delighted to be working with Genethon, a leader in this field, to accelerate this adaptation. We are confident that the outcome of this partnership will be a game changer for both industry and patients”.